In what could be a major pharmaceutical breakthrough, research published online in The FASEB Journal describes how scientists from St George's, University of London have devised a one-two punch to stop HIV. First the report describes a new protein that can kill the virus when used as a microbicide. Then the report shows how it might be possible to manufacture this protein in quantities large enough to make it affordable for people in developing countries.

Focusing HIV drug development on immune cells called macrophages instead of traditionally targeted T cells could bring us closer to eradicating the disease, according to new research from University of Florida and five other institutions.

A doctoral thesis presented at the Sahlgrenska Academy, University of Gothenburg, Sweden, shows that it is possible to describe and quantify the relationships between dose, concentration and effectiveness of several drugs against HIV/AIDS and malaria.

Nature study reveals long-sought atomic structure of key enzyme and suggests new approach for drug development

NewYork-Presbyterian Hospital/Weill Cornell Medical Center's Dr. Roy Gulick is lead investigator of phase 3 multicenter trial

Researchers at North Carolina State University have discovered that adding tiny bits of gold to a failed HIV drug rekindle the drug's ability to stop the virus from invading the body's immune system.

Most of us have missed a dose of antibiotic or forgotten to take a daily vitamin. But when the stakes are higher — as they are for people with HIV/AIDS — a skipped pill could mean the difference between health and hazard for the entire population.

The advent of effective medications for treating HIV dramatically improved the outlook for both adults and children infected with HIV who had access to treatment, but the optimal timing for starting treatment remains controversial, particularly in children.

An experimental anti-HIV gel is safe for women to use on a daily basis, according to researchers at the University of Alabama at Birmingham (UAB) and the University of Pittsburgh School of Medicine.

A study to assess the adverse effects of anti-retroviral drugs shows that two of the widely used HIV drugs are associated with an increased risk of heart attack/the formation of blood clots in the heart. With the use of Didanosine; the risk of developing a heart attack increases by 49%, with Abacavir; the increased risk is 90%.

A mutation in a little-studied structural region of the AIDS virus can cause resistance to several HIV drugs, according to a study published in PLoS Medicine by Gilda Tachedjian and colleagues from Australia, Canada, and the United States.

People who do not have HIV but seek antiretroviral medications following high-risk sexual encounters are very likely to complete the full monthlong drug regimen, according to a new UCLA AIDS Institute study. Moreover, there is a strong demand for publicly available post-exposure prophylaxis among high-risk populations in Los Angeles County.